Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Nivolumab-Induced Arthritis

Catherine Strahle, DO, Nathalie E. Chalhoub, MD, & Avis Ware, MD  |  October 18, 2018

Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Cancercase reportimmune checkpoint inhibitor (ICI)nivolumabPsoriatic Arthritisskin psoriasis

Study Reveals Lupus Is a Leading Cause of Death in U.S. Women

Kimberly J. Retzlaff  |  October 18, 2018

Systemic lupus erythematosus (SLE) is a leading cause of death among young women, according to an August 2018 study in Arthritis & Rheumatology.1 To help determine where SLE ranks among causes of death, Eric Y. Yen, MD, and Ram Raj Singh, MD, conducted a population-based study using nationwide mortality counts for all female residents of…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:death rateGendermortality rateRheumatology Research Foundation

A Historical Look at the Characterization of Lupus as a Systemic Disease

Ruth Jessen Hickman, MD  |  October 18, 2018

The disease called systemic lupus erythematosus (SLE) went through many different stages of classification before reaching the modern criteria reflecting our current understanding of its pathogenesis. In 1872, the Viennese dermatologist Moriz Kaposi, MD, published a paper, “New Contributions to Knowledge of Lupus Erythematosus,” which provided a significant leap forward in the characterization of this…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Classification CriteriaDr. Moriz KaposiHistoryLost & Found

The Case of a 13-Year-Old Girl with Life-Threatening Lupus Onset

Charles Radis, DO  |  October 18, 2018

I glanced up from Amanda Wolf’s chart as the emergency department nurse, followed by the lab technician (tech), followed by the electrocardiogram (ECG) tech flowed into cubicle No. 5. John Benner, MD, pulled up a chair to review the case with me at the nursing station. “Here’s what we’ve got. Thirteen-year-old girl with a one-week…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:cyclophosphamidekidney failurePericarditisSteroids

Social Media May Reduce Depression Risk for Older People with Pain

Cheryl Platzman Weinstock  |  October 10, 2018

(Reuters Health)—Online socializing may weaken the tie between pain and depression for older people, a U.S. study suggests. People in chronic pain are at risk of depression to start with. When pain makes them stay home more, interacting with friends and family less, it only adds to this risk, the researchers write in the Journals…

Filed under:ConditionsPain SyndromesTechnology Tagged with:Chronic painDepressiononline socializingSocial Media

Trio Wins Chemistry Nobel for Work on Antibody Drugs & Detergents

Daniel Dickson and Ben Hirschler  |  October 4, 2018

STOCKHOLM/LONDON (Reuters)—Two Americans and a Briton won the 2018 Nobel Prize for Chemistry on Wednesday for harnessing the power of evolution to generate novel proteins used in everything from environmentally friendly detergents and biofuels to cancer drugs. The fruits of this work include the world’s top-selling prescription medicine – the antibody injection Humira sold by…

Filed under:AwardsDrug UpdatesProfessional TopicsRheumatoid Arthritis Tagged with:AbbVieantibody drugs and detergentsAwardsFrances ArnoldGeorge SmithGregory WinterHumira

ACR Policy: The Mouse That Roared

Chris Morris, MD  |  September 30, 2018

Do you remember the 1959 movie, The Mouse That Roared? Through a few small actions, the Duchy of Grand Fenwick, a small, often overlooked principality, becomes a superpower on the world map overnight. In many ways, rheumatology has been in the same position. We are a small specialty; we don’t have well-known diseases. Although our…

Filed under:From the CollegeLegislation & Advocacy Tagged with:RheumPACRheumPAC investmentThe Mouse that Roared

Researchers Fight Cellular Senescence, Low-Grade Inflammation

Thomas R. Collins  |  September 20, 2018

AMSTERDAM—Low-grade inflammation in older adults can impede immune responsiveness, and researchers have shed light on how this happens. They have developed a short-term treatment that blocks inflammation and boosts the immune response, an expert said at EULAR: the Annual European Congress of Rheumatology. The findings were presented in a session on cellular senescence related to…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:inflammationknee osteoarthritissenescencesenescent

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  September 20, 2018

Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

Filed under:ConditionsDrug UpdatesMyositisOther Rheumatic Conditions Tagged with:immune-related adverse eventsirAEsmyositisnivolumab

New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse

Elizabeth Hofheinz, MPH, MEd  |  September 20, 2018

Imagine telling a patient “You’re in remission!” and finding out it’s not true. The last thing you want to do is get it wrong clinically and put your patient on an emotional rollercoaster. With large vessel vasculitis (LVV) in particular, physicians struggle to be accurate, to determine if indeed the disease has gone away or…

Filed under:Vasculitis Tagged with:large-vessel vasculitisrelapseRemission

  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences